Dr. Cattamanchi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 The City Drive South
Orange, CA 92868Phone+1 714-456-2959Fax+1 714-456-3597
Education & Training
- University of California (San Francisco)Fellowship, Pulmonary Disease and Critical Care Medicine, 2005 - 2008
- University of California (San Francisco)Residency, Internal Medicine, 2003 - 2005
- University of California San Francisco School of MedicineClass of 2003
Certifications & Licensure
- CA State Medical License 2005 - 2026
- American Board of Internal Medicine Pulmonary Disease
Clinical Trials
- GeneXpert Performance Evaluation for Linkage to Tuberculosis Care Start of enrollment: 2018 Oct 22
- Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial) Start of enrollment: 2020 Jul 13
Publications & Presentations
PubMed
- Identifying mechanisms by which social determinants of health impact TB diagnostic evaluation uptake in Uganda: a qualitative study.Talemwa Nalugwa, Kristi Sidney Annerstedt, Sarah Nabwire, Nora S West, Jillian L Kadota
International Journal for Equity in Health. 2025-03-14 - C-Reactive Protein-based Screening of People with Tuberculosis Symptoms: A Diagnostic Accuracy Study.Brigitta Derendinger, Tessa K Mochizuki, Danaida Marcelo, Deepa Shankar, Wilson Mangeni
American Journal of Respiratory and Critical Care Medicine. 2025-03-01 - Stool processing methods for Xpert Ultra testing in childhood tuberculosis: A prospective, multi-country accuracy study.Devan Jaganath, Pamela Nabeta, Mark P Nicol, Robert Castro, Peter Wambi
Medrxiv. 2024-12-18
Journal Articles
- Association of Rapid Molecular Testing with Duration of Respiratory Isolation for Patients with Possible Tuberculosis in a US HospitalBarbara Haller, Adithya Cattamanchi, Julie Higashi, JAMA
Press Mentions
- BRAF Mutation in Non-Small Cell Lung Cancer: Your FAQs AnsweredMarch 7th, 2025
- The Fight Against TB Was Frozen in Time, Until Now. See Its FutureMarch 4th, 2025
- Congratulations to Mulago Hospital’s Dr William WorodriaMay 17th, 2023
- Join now to see all
Grant Support
- Partnerships for Research in Implementation Science for Equity in Heart and Lung diseases training program (PRISE-HL T32)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2023–2028
- Partnerships for Research in Implementation Science for Equity in Heart and Lung diseases training program (PRISE-HL T32)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2023–2028
- PROgression of Tuberculosis infECTion in young children living with and without HIV: the PROTECT studyUNIVERSITY OF CALIFORNIA-IRVINE2023–2028
- Partnerships for Research in Implementation Science for Equity in Heart and Lung diseases training program (PRISE-HL T32)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2023–2028
- C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB StudyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2025
- C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB StudyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2025
- C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB StudyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2025
- C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB StudyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2025
- Childhood ‘Omics’ and Mycobacterium tuberculosis-derived BiOsignatures (COMBO) for TB diagnosis in high HIV prevalence settingsUNIVERSITY OF CALIFORNIA-IRVINE2020–2025
- Childhood ‘Omics’ and Mycobacterium tuberculosis-derived BiOsignatures (COMBO) for TB diagnosis in high HIV prevalence settingsUNIVERSITY OF CALIFORNIA-IRVINE2020–2025
- Childhood ‘Omics’ and Mycobacterium tuberculosis-derived BiOsignatures (COMBO) for TB diagnosis in high HIV prevalence settingsUNIVERSITY OF CALIFORNIA-IRVINE2020–2025
- Rapid Research for Diagnostics Development in TB Network (R2D2 TB Network)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2025
- Rapid Research for Diagnostics Development in TB Network (R2D2 TB Network)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2025
- Options for Delivery of Short-Course Tuberculosis Preventive Therapy: The 3HP Options TrialUNIVERSITY OF CALIFORNIA-IRVINE2018–2025
- Options for Delivery of Short-Course Tuberculosis Preventive Therapy: The 3HP Options TrialUNIVERSITY OF CALIFORNIA-IRVINE2018–2025
- Options for Delivery of Short-Course Tuberculosis Preventive Therapy: The 3HP Options TrialUNIVERSITY OF CALIFORNIA-IRVINE2018–2025
- Options for Delivery of Short-Course Tuberculosis Preventive Therapy: The 3HP Options TrialUNIVERSITY OF CALIFORNIA-IRVINE2018–2025
- Immunodiagnosis Of Active Tuberculosis In Hiv-Infected PatientsNational Heart, Lung, And Blood Institute2009–2012
- TB Guidline Observation And Adherence In Low Income Countries (Tb Goal)National Institute Of Allergy And Infectious Diseases2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: